Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

BACKGROUND AND AIMS: Data from an all-cases post-marketing study were used to evaluate the safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease [CD]. METHODS: Patients received adalimumab for 24 weeks. Data from all patients [n = 1693] were used for the safety assessment....

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Haruhiko, Watanabe, Mamoru, Matsui, Toshiyuki, Hase, Hidenori, Okayasu, Motohiro, Tsuchiya, Tsuyoshi, Shinmura, Yasuhiko, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007524/
https://www.ncbi.nlm.nih.gov/pubmed/26961546
http://dx.doi.org/10.1093/ecco-jcc/jjw060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007524/
https://www.ncbi.nlm.nih.gov/pubmed/26961546
http://dx.doi.org/10.1093/ecco-jcc/jjw060

Ejemplares similares